Compounds > isonitrosoacetophenone
Page last updated: 2024-12-11

isonitrosoacetophenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9566037
MeSH IDM0159990

Synonyms (58)

Synonym
(2e)-2-hydroxyimino-1-phenylethanone
nsc-25388
nsc25388
glyoxal, 1-phenyl-, 2-oxime
phenylglyoxal monoxime
2-hydroxyiminoacetophenone
brn 2041691
nsc 1330
einecs 208-539-5
glyoxal, phenyl-, 2-oxime
phenylglyoxal 2-oxime
nsc1330
glyoxal, 2-oxime
benzeneacetaldehyde, aldoxime
acetophenone, 2-hydroxyimino-
2-(hydroxyimino)acetophenone
benzoylformaldoxime
isonitrosoacetophenone
inaf
532-54-7
phenylglyoxal aldoxime
nsc-1330
2-isonitrosoacetophenone
wln: qnu1vr
2-isonitrosoacetophenone, 97%
P0181
phenylglyoxaldoxime
?-(hydroxyimino)acetophenone
?-isonitrosoacetophenone
2-oxo-2-phenylacetaldehyde oxime
A829477
(2e)-2-hydroxyimino-1-phenyl-ethanone
(1e)-2-oxo-2-phenylacetaldehyde oxime
unii-ffe56234vn
ffe56234vn ,
4-07-00-02132 (beilstein handbook reference)
(2e)-2-(n-hydroxyimino)-1-phenylethan-1-one
PS-4479
mu-(hydroxyimino)acetophenone
einecs 281-315-2
AKOS015888584
DTXSID5060198
mfcd00002122
1-oxo(phenyl)ethanal oxime #
oximinoacetophenone
benzeneacetaldehyde, .alpha.-oxo-, aldoxime
benzoyl formaldehyde-1-oxime
STR03375
isonitrosoacetophenon
22668-53-7
omega-(hydroxyimino)acetophenone
isonitrosoacetophenone [mi]
glyoxal, phenyl-, aldoxime
.alpha.-(hydroxyimino)acetophenone
.alpha.-(hydroximino)acetophenone
(e)-2-oxo-2-phenylacetaldehyde oxime
CS-W018181
(e)-2-oxo-2-phenylacetaldehydeoxime
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.27 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzoic acid
Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.		2.110benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
riluzole
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.		2.1310benzothiazoles
phenylglyoxal
[no description available]		3.5580phenylacetaldehydes
phenyl di-n-pentylphosphinate
phenyl di-n-pentylphosphinate: inhibitor of neuropathy target esterase (neurotoxic esterase)		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Apnea, Obstructive Sleep
[description not available]		03.5240
Auricular Fibrillation
[description not available]		03.5240
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		03.5240
Sleep Apnea, Obstructive
A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)		03.5240
Disease Resistance
The capacity of an organism to defend itself against pathological processes or the agents of those processes. This most often involves innate immunity whereby the organism responds to pathogens in a generic way. The term disease resistance is used most frequently when referring to plants.		02.1110
ALS - Amyotrophic Lateral Sclerosis
[description not available]		02.1310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1310
Amyotrophic Lateral Sclerosis
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)		02.1310